NASDAQ:KNSA

Kiniksa Pharmaceuticals Competitors

$17.69
-0.44 (-2.43 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.47
Now: $17.69
$18.14
50-Day Range
$16.68
MA: $20.66
$23.97
52-Week Range
$14.51
Now: $17.69
$28.67
Volume425,618 shs
Average Volume507,073 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.03

Competitors

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Vs. AVIR, SAGE, BHVN, HCM, EBS, and ARNA

Should you be buying KNSA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kiniksa Pharmaceuticals, including Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), and Arena Pharmaceuticals (ARNA).

Atea Pharmaceuticals (NASDAQ:AVIR) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Atea Pharmaceuticals and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Valuation and Earnings

This table compares Atea Pharmaceuticals and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Insider and Institutional Ownership

42.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 70.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Atea Pharmaceuticals and Kiniksa Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Kiniksa Pharmaceuticals00303.00

Atea Pharmaceuticals presently has a consensus price target of $69.3333, indicating a potential upside of 22.69%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given Kiniksa Pharmaceuticals' higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Sage Therapeutics (NASDAQ:SAGE) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Sage Therapeutics and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Volatility and Risk

Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sage Therapeutics and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million651.04$-680,240,000.00($13.38)-5.73
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Kiniksa Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by company insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Sage Therapeutics and Kiniksa Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Kiniksa Pharmaceuticals00303.00

Sage Therapeutics presently has a consensus price target of $87.0625, indicating a potential upside of 13.64%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Sage Therapeutics.

Summary

Kiniksa Pharmaceuticals beats Sage Therapeutics on 9 of the 13 factors compared between the two stocks.

Biohaven Pharmaceutical (NYSE:BHVN) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Biohaven Pharmaceutical and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Volatility and Risk

Biohaven Pharmaceutical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

Earnings & Valuation

This table compares Biohaven Pharmaceutical and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.36
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Biohaven Pharmaceutical and Kiniksa Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Kiniksa Pharmaceuticals00303.00

Biohaven Pharmaceutical presently has a consensus price target of $96.4545, indicating a potential upside of 39.00%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Summary

Kiniksa Pharmaceuticals beats Biohaven Pharmaceutical on 7 of the 11 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Hutchison China MediTech and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Volatility and Risk

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

Earnings & Valuation

This table compares Hutchison China MediTech and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Hutchison China MediTech has higher revenue and earnings than Kiniksa Pharmaceuticals. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 70.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Hutchison China MediTech and Kiniksa Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Kiniksa Pharmaceuticals00303.00

Hutchison China MediTech presently has a consensus price target of $40.00, indicating a potential upside of 36.80%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Hutchison China MediTech.

Summary

Hutchison China MediTech beats Kiniksa Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Emergent BioSolutions and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Volatility and Risk

Emergent BioSolutions has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Emergent BioSolutions and Kiniksa Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Kiniksa Pharmaceuticals00303.00

Emergent BioSolutions presently has a consensus price target of $109.8333, indicating a potential upside of 42.00%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Emergent BioSolutions.

Earnings & Valuation

This table compares Emergent BioSolutions and Kiniksa Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.73$54.50 million$2.9126.58
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Emergent BioSolutions has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Summary

Emergent BioSolutions beats Kiniksa Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 70.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kiniksa Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kiniksa PharmaceuticalsN/A-53.65%-49.11%
Arena PharmaceuticalsN/A-33.17%-30.41%

Risk and Volatility

Kiniksa Pharmaceuticals has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Kiniksa Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kiniksa Pharmaceuticals00303.00
Arena Pharmaceuticals001503.00

Kiniksa Pharmaceuticals currently has a consensus target price of $37.00, indicating a potential upside of 109.16%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 38.48%. Given Kiniksa Pharmaceuticals' higher probable upside, research analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Arena Pharmaceuticals.

Valuation and Earnings

This table compares Kiniksa Pharmaceuticals and Arena Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92
Arena Pharmaceuticals$806.43 million4.96$397.55 million$7.698.62

Arena Pharmaceuticals has higher revenue and earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Kiniksa Pharmaceuticals on 8 of the 11 factors compared between the two stocks.


Kiniksa Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.